Dou, Xiaoyang
Xiao, Yu
Shen, Chao
Wang, Kitty
Wu, Tong http://orcid.org/0000-0001-9968-9909
Liu, Chang
Li, Yini http://orcid.org/0000-0003-2213-0650
Yu, Xianbin
Liu, Jun http://orcid.org/0000-0002-2498-9963
Dai, Qing http://orcid.org/0000-0002-8578-1568
Pajdzik, Kinga
Ye, Chang http://orcid.org/0000-0003-0236-5671
Ge, Ruiqi
Gao, Boyang
Yu, Jianhua http://orcid.org/0000-0002-0326-3223
Sun, Shuying http://orcid.org/0000-0002-8449-7370
Chen, Mengjie http://orcid.org/0000-0003-1579-087X
Chen, Jianjun http://orcid.org/0000-0003-3749-2902
He, Chuan http://orcid.org/0000-0003-4319-7424
Funding for this research was provided by:
Foundation for the National Institutes of Health (RM1 HG008935, R01 HL155909, R01 ES030546, R01 CA251150, R01 NS107347, RF1 NS113820, RF1 NS127925, R01 AG078948, R01 HG012927, R01 CA236399, R01 CA243386, R01 CA271497, R01 DK124116)
National Science Foundation (NSF 2016307)
Article History
Received: 15 June 2022
Accepted: 21 July 2023
First Online: 28 August 2023
Competing interests
: C.H. is a scientific founder, a member of the scientific advisory board and equity holder of Aferna Bio, Inc. and AccuaDX Inc., a scientific co-founder and equity holder of Accent Therapeutics, Inc., and a member of the scientific advisory board of Rona Therapeutics. T.W. is a shareholder of AccuraDX, Inc. The other authors declare no competing interests.